TP53 mutation and survival in aggressive B cell lymphoma.

LHA-ID
7R9DC0C9EG-2
Summary

The impact of TP53 mutations on prognosis in aggressive B-NHL was investigated within the RICOVER-60 trial. TP53 mutations were present in 63 of 265 patients (23.8%). TP53 mutation was associated with higher LDH (65% vs. 37%; p<0.001), higher international prognostic index-Scores (IPI 4/5 27% vs. 12%; p=0.025), and B-symptoms (41% vs. 24%; p=0.011). Patients with TP53 mutation were less likely to obtain a complete remission CR/CRu (CR unconfirmed) 61.9% (mut) vs. 79.7% (wt) (p=0.007). TP53 mutations were associated with decreased event-free (EFS), progression-free (PFS), and overall survival (OS) (median observation time of 40.2 months): the 3 year EFS, PFS and OS were 42% (vs. 60%; p=0.012), 42% (vs. 67.5%; p<0.001) and 50% (vs. 76%; p<0.001) for the TP53 mutation group. TP53 mutations should be considered for risk models in DLBCL and strategies to improve outcome for patients with mutant TP53 must be developed.

Abstract
TP53 is mutated in 20-25% of aggressive B-cell lymphoma (B-NHL). To date, no studies have addressed the impact of TP53 mutations in prospective clinical trial cohorts. To evaluate the impact of TP53 mutation to current risk models in aggressive B-NHL, we investigated TP53 gene mutations within the RICOVER-60 trial. Of 1,222 elderly patients (aged 61-80 years) enrolled in the study and randomized to six or eight cycles of CHOP-14 with or without Rituximab (NCT00052936), 265 patients were analyzed for TP53 mutations. TP53 mutations were demonstrated in 63 of 265 patients (23.8%). TP53 mutation was associated with higher LDH (65% vs. 37%; p 
DOI
10.1002/ijc.30838
Publication Date
Journal
International journal of cancer
Journal Volume
141
Journal Number
7
Journal Section
1381-1388
Corresponding Author
Thorsten Zenz
Corresponding Author Institution

Thorsten Zenz, MD
Molecular Therapy in Haematology and Oncology (G250), National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ)
Im Neuenheimer Feld 460
69120 Heidelberg, Germany

Corresponding Author email
Publication Type
Human Disease Ontology Concept